Mumbai, May 12 -- Dr Reddy's Laboratories, which received regulatory approval for generic semaglutide in Canada on 29 April, is gearing up to launch the drug in the next few days, its top leadership told reporters in a press briefing.

The drugmaker, which also launched a generic semaglutide injection in India in March under the brand name 'Obeda', is launching oral tablets of the popular weight-loss drug in the country in the next few days, as well as adding more brands to its portfolio, management said.

"It's all about logistics. In the next [few] days, there will be semaglutide in the Canadian market," chief executive officer Erez Israeli told reporters on Tuesday. The Hyderabad-headquartered drugmaker was the first to receive approva...